V2X, Inc. announced strong Q3 2026 results with revenue of $1.27 billion, up 9% year-over-year, and net income of $32 million, a 30% increase. Adjusted earnings per share rose 19% to $1.64. The company also improved its net leverage ratio and reported a backlog of $12.8 billion. Due to strong performance and demand, V2X raised its full-year 2026 guidance across revenue, EBITDA, and earnings per share, signaling confidence in continued growth and strategic investments.
V2X's Q3 2026 results provide context for readers. Among 135 Industrials-sector US stocks on Pluang, 66 rose and 69 fell as of Nov 03, 2026 04:01 WIB. Notable movers include NAT at USD 7.32 (-7.46%), SARO at USD 25.08 (+7.25%, 42% Sell / 58% Buy), and HWM at USD 212.85 (+6.77%, 10% Sell / 90% Buy).
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
The FDA placed Bright Minds Biosciences' planned Phase 2 epilepsy trial for BMB-101 on partial clinical hold due to toxicity findings in mice and insufficient pharmacokinetic and juvenile-toxicity data. This action caused a sharp decline in the compa...
NEAR governance approved a plan to reduce the maximum annual issuance of the NEAR token from 2.5% to 1.6%. This change aims to slow the rate at which new tokens enter circulation, potentially impacting staking rewards by lowering them. The plan inclu...
